Related Experiment Video
Updated: Oct 2, 2025

An Educational Video Demonstration of How to Prone a Critically Ill Intubated Patient
Published on: November 30, 2022
Benefits of Using Dapsone in Patients Hospitalized with COVID-19
Badar A Kanwar1, Asif Khattak1, Jenny Balentine1
1Department of Intensive Care Unit and Neonatal Intensive Care, Hunt Regional Hospital, Greenville, TX 75401, USA.
Dapsone may improve outcomes for hospitalized COVID-19 patients. This study found dapsone reduced death or long-term acute care discharge and increased home discharge rates, warranting further investigation.
Area of Science:
- Medical Research
- Pharmacology
- Infectious Diseases
Background:
- Hypoxia due to lung inflammation is a primary cause of death in severe COVID-19.
- Previous studies suggested potential benefits of dapsone in this patient population.
Purpose of the Study:
- To evaluate the impact of dapsone on discharge outcomes in hospitalized COVID-19 patients.
- To compare outcomes between patients receiving dapsone and those receiving standard care.
Main Methods:
- Retrospective chart review of hospitalized COVID-19 patients.
- 2x2 table analysis to compare outcomes between groups.
Main Results:
- Patients receiving dapsone had a significantly lower risk of death or discharge to long-term acute care (LTAC) (RR=0.52).
- Dapsone administration was associated with a higher likelihood of discharge home (RR=2.7).
Conclusions:
- Dapsone may be associated with improved clinical outcomes in COVID-19 patients.
- Further urgent investigation via a larger, blinded randomized trial is recommended to confirm these findings.
More Related Videos
09:03Nasal Brushing Sampling and Processing Using Digital High Speed Ciliary Videomicroscopy – Adaptation for the COVID-19 Pandemic
Published on: November 7, 2020
07:30Design of Cecal Ligation and Puncture and Intranasal Infection Dual Model of Sepsis-Induced Immunosuppression
Published on: June 15, 2019
Related Concept Videos
PPE Use in Healthcare Settings II: Doffing
Hand hygiene
Hand washing...
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Transmission-based Precautions II: Airborne and Protective Environment
Airborne precautions:
Use airborne precautions when treating patients known or suspected to have diseases that spread through the air—for example, tuberculosis or measles. These organisms are present in smaller droplets expelled by an infected person and...
Transmission-based Precautions I: Contact, Enteric, and Droplets
Contact Precautions:
Contact precautions are the measures taken to prevent the transmission of infectious agents, especially epidemiologically important microorganisms such as MRSA or influenza, primarily transmitted through direct or indirect contact with an...